Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 338

1.

Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.

Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P.

J Natl Cancer Inst. 2006 Oct 4;98(19):1397-405.

PMID:
17018786
2.

Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.

Lacey JV Jr, Leitzmann MF, Chang SC, Mouw T, Hollenbeck AR, Schatzkin A, Brinton LA.

Cancer. 2007 Apr 1;109(7):1303-11. Erratum in: Cancer. 2007 Aug 15;110(4):937.

3.

Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.

Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Danforth KN, Park Y, Brinton LA.

Br J Cancer. 2012 Sep 25;107(7):1181-7. doi: 10.1038/bjc.2012.397. Epub 2012 Aug 28.

4.

Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.

Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C.

Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1724-31.

5.

Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort.

Brinton LA, Schwartz L, Spitz MR, Park Y, Hollenbeck AR, Gierach GL.

Cancer Causes Control. 2012 Mar;23(3):487-96. doi: 10.1007/s10552-012-9904-2. Epub 2012 Feb 25.

6.

Breast cancer risk in relation to the interval between menopause and starting hormone therapy.

Beral V, Reeves G, Bull D, Green J; Million Women Study Collaborators.

J Natl Cancer Inst. 2011 Feb 16;103(4):296-305. doi: 10.1093/jnci/djq527. Epub 2011 Jan 28.

7.

Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?

Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, Brinton LA.

Int J Cancer. 2013 Jan 15;132(2):417-26. doi: 10.1002/ijc.27623. Epub 2012 Aug 30.

8.

Hormone therapy and ovarian cancer.

Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O.

JAMA. 2009 Jul 15;302(3):298-305. doi: 10.1001/jama.2009.1052.

PMID:
19602689
9.

Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.

Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3150-60. doi: 10.1158/1055-9965.EPI-08-0435.

10.

Menopausal hormone replacement therapy and risk of ovarian cancer.

Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C.

JAMA. 2002 Jul 17;288(3):334-41. Erratum in: JAMA 2002 Nov 27;288(20):2544.

PMID:
12117398
11.

A prospective study of postmenopausal hormone use and ovarian cancer risk.

Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE.

Br J Cancer. 2007 Jan 15;96(1):151-6. Epub 2006 Dec 19.

12.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL.

J Natl Cancer Inst. 2013 Apr 17;105(8):526-35. doi: 10.1093/jnci/djt043. Epub 2013 Mar 29.

13.

Hormone therapy and ovarian borderline tumors: a national cohort study.

Mørch LS, Løkkegaard E, Andreasen AH, Kjær SK, Lidegaard Ø.

Cancer Causes Control. 2012 Jan;23(1):113-20. doi: 10.1007/s10552-011-9860-2. Epub 2011 Oct 29.

PMID:
22037908
14.

Hormone replacement therapy and cancer.

[No authors listed]

Gynecol Endocrinol. 2001 Dec;15(6):453-65. Review.

PMID:
11826770
15.

Estrogen-progestin replacement therapy and endometrial cancer.

Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM.

J Natl Cancer Inst. 1997 Aug 6;89(15):1110-6.

PMID:
9262248
16.

Hormone therapy and different ovarian cancers: a national cohort study.

Mørch LS, Løkkegaard E, Andreasen AH, Kjaer SK, Lidegaard O.

Am J Epidemiol. 2012 Jun 15;175(12):1234-42. doi: 10.1093/aje/kwr446. Epub 2012 Apr 19.

PMID:
22517811
18.

Postmenopausal estrogen and progestin use in relation to breast cancer risk.

Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600.

19.

Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen.

Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV.

Int J Cancer. 2010 Dec 15;127(12):2928-35. doi: 10.1002/ijc.25515.

20.

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

Ross RK, Paganini-Hill A, Wan PC, Pike MC.

J Natl Cancer Inst. 2000 Feb 16;92(4):328-32.

PMID:
10675382

Supplemental Content

Support Center